NCT05716126View on ClinicalTrials.gov

Single Dose Mass Balance Study With [14C]Iruplinalkib (WX-0593) In Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 15, 2020

Primary Completion Date

December 15, 2020

Study Completion Date

January 13, 2021

Conditions
Healthy
Interventions
DRUG

[14C]Iruplinalkib (WX-0593)

Volunteer will receive a single oral dose of 120 mg \[14C\]Iruplinalkib (WX-0593) as a solution on Day 1

Trial Locations (1)

215006

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT05716126 - Single Dose Mass Balance Study With [14C]Iruplinalkib (WX-0593) In Healthy Male Volunteers | Biotech Hunter | Biotech Hunter